Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation by Aljitawi, Omar S. et al.
Hyperbaric oxygen improves engraftment of ex-vivo expanded
and gene transduced human CD34+ cells in a murine model of
umbilical cord blood transplantation
Omar S. Aljitawia,*, Yinghua Xiaoa, Jeff D. Eskewb, Nikhil K. Parelkarb, Megan Swinkb, Jeff
Radelc, Tara L. Lina, Bruce F. Kimlerd, Jonathan D. Mahnkene, Joseph P. McGuirka, Hal E.
Broxmeyerf, and George Vielhauerb,g
Yinghua Xiao: xyhpotato@gmail.com; Jeff D. Eskew: jeskew@kumc.edu; Nikhil K. Parelkar: nparelkar@kumc.edu; Megan
Swink: mswink@kumc.edu; Jeff Radel: JRADEL@kumc.edu; Tara L. Lin: tlin@kumc.edu; Bruce F. Kimler:
bkimler@kumc.edu; Jonathan D. Mahnken: jmahnken@kumc.edu; Joseph P. McGuirk: jmcguirk@kumc.edu; Hal E.
Broxmeyer: hbroxmey@iupui.edu; George Vielhauer: gvielhauer@kumc.edu
aDivision of Hematology/Oncology and Blood and Marrow Transplantation Program, 2330
Shawnee Mission Parkway, University of Kansas Medical Center, Kansas City, KS 66205
bUniversity of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS
66160
cOccupational Therapy Education, 3901 Rainbow Blvd, University of Kansas Medical Center,
Kansas City, KS 66160
dRadiation Oncology, 3901 Rainbow Blvd, University of Kansas Medical Center, Kansas City, KS
66160
eBiostatistics, 3901 Rainbow Blvd, University of Kansas Medical Center, Kansas City, KS 66160
fDepartment of Microbiology and Immunology, Indiana University School of Medicine,635 Barnhill
Drive, Indianapolis, Indiana 46202
gDepartment of Urology, 3901 Rainbow Blvd, University of Kansas Medical Center, Kansas City,
KS
Abstract
Delayed engraftment and graft failure represent major obstacles to successful umbilical cord blood
(UCB) transplantation. Herein, we evaluated the use of hyperbaric oxygen (HBO) therapy as an
intervention to improve human UCB stem/progenitor cell engraftment in an immune deficient
mouse model. Six-to eight-week old NSG mice were sublethally irradiated 24 hours prior to
CD34+ UCB cell transplant. Irradiated mice were separated into a non-HBO group (where mice
remained under normoxic conditions) and the HBO group (where mice received two hours of
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HBO therapy; 100% oxygen at 2.5 atmospheres absolute). Four hours after completing HBO
therapy, both groups intravenously received CD34+ UCB cells that were transduced with a
lentivirus carrying luciferase gene and expanded for in vivo imaging. Mice were imaged and then
sacrificed at one of 10 times up to 4.5 months post-transplant. HBO treated mice demonstrated
significantly improved bone marrow, peripheral blood , and spleen (p=0.0293) retention and
subsequent engraftment. In addition, HBO significantly improved peripheral, spleen and bone
marrow engraftment of human myeloid and B-cell subsets. In vivo imaging demonstrated that
HBO mice had significantly higher ventral and dorsal bioluminescence values. These studies
suggest that HBO treatment of NSG mice prior to UCB CD34+ cell infusion significantly
improves engraftment.
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Introduction
Umbilical cord blood (UCB) may be the only allogeneic transplant option for patients who
lack matched sibling or well matched unrelated donors. Unfortunately, UCB units have
limited cell doses available for transplantation, which translates into delayed neutrophil and
platelet engraftment and higher rates of engraftment failure [1; 2; 3]. This delay in
engraftment is also associated with a delay in immune reconstitution post cord blood
transplantation[1; 3; 4; 5; 6], which leads to higher incidence of infections early post UCB
transplant[1; 5; 7; 8].
Hematopoietic stem cell (HSC) homing precedes engraftment, which corresponds to the
proliferation and differentiation of hematopoietic stem cells to produce mature, functional
hematopoietic cells within the bone marrow[9]. During HSC homing, HSCs actively cross
the blood/bone marrow endothelium barrier and lodge at least transiently in the bone
marrow compartment[10]. This process is fairly rapid and occurs within hours and no longer
than two days after stem cell infusion[10]. HSC homing is mediated by the binding of
CXCR4 receptor on the surface of HSCs to their ligand, stromal cell-derived factor-1
(SDF-1/CXCL12) expressed by bone marrow endothelium and endosteum[11; 12].
Several approaches have been investigated to improve UCB cell homing/engraftment[1; 3].
For example, after mouse bone marrow studies in lethally irradiated mouse recipients[13],
inhibition of dipeptidylpeptidase 4 (DDP4)/CD26 activity by pretreating purified CD34+
human CB cells with Diprotin A significantly enhanced engraftment of HSCs from human
UCB into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice[14]. A
DPP4 inhibitor, sitagliptin, after studies of DPP4 inhibitor in mouse recipients enhanced
engraftment of mouse bone marrow cells[15], has been investigated in a clinical trial with
encouraging results in engraftment of adults with hematological malignancies after single
unit UCB transplantation[16], Another strategy involves direct intrabone administration of
cord blood cells into the superior-posterior iliac crest under rapid general anesthesia. Though
this strategy produced impressive results in some studies[17], another study did not show
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similar results[18]. In exploring defects in cord blood stem cell homing, it was found that
cord blood CD34+ cells have reduced alpha1,3-fucosyltransferase (FucT) expression and
activity, which results in absence of cord blood stem cell surface ligands needed to interact
with adhesion molecules at time of stem cell homing[19]. Although the use of recombinant
human FucTVI corrected the deficiency and helped generate ligands, these changes
enhanced initial interaction with microvessels but not homing to bone marrow, according to
one study[19]. Another study argued that ex vivo fucosylation improved engraftment in a
murine model through enhanced homing[20]. Despite this progress in understanding the
biology of UCB homing and engraftment, there is an urgent need to identify safe and
practical interventions to enhance UCB homing and engraftment for transplant patients.
In this study, we evaluated the use of hyperbaric oxygen (HBO) therapy as an intervention
to improve UCB stem/progenitor cell engraftment. HBO involves inhalation of 100%
oxygen intermittently under a pressure greater than 1 atmosphere (ATM), which results in
both mechanical effects related to increased pressure and physiologic effects related to
hyperoxia[21]. We hypothesized that HBO therapy given prior to UCB CD34+ cell infusion
will result in improved engraftment of intravenously infused UCB CD34+ cells. In these
experiments, we treated sublethally irradiated NOD/SCID/IL-2Rgcnull (NSG) mice with
HBO 6 hours prior to cord blood CD34+ cell infusion and assessed their bone marrow
retention and their engraftment as a continuum at several time points. We have chosen NSG
mice as they were reported to more efficiently support human cell engraftment [22]. In order
to avoid any potential impact of HBO on the actual infused UCB CD34+ cells, we chose to
infuse the UCB CD34+ cells 6 hours after the start of HBO therapy. In these studies, UCB
CD34+ cells were transduced with luciferase lentivirus to allow for in vivo imaging of
transplanted UCB CD34+ cells.
Materials and Methods
Isolation of CD 34+ cells from UCB units
UCB units freshly obtained from St. Louis Cord Blood Bank were processed for CD34+
selection according to manufacturer’s recommendation using StemSep® Human CD34
Positive Selection Cocktail purchased from (STEMCELL Technologies). Isolated CD34+
cells were then transduced and expanded as described in the next section.
UCB CD34 cell transduction
Lentivirus particles harboring the Luc2/mCherry gene and pseudotyped with VSV-G
envelope was used to transduce CD 34+ cells at a multiplicity of Infection (MOI) of 10 – 20.
The method of spin-infection was used as previously described [23]. Briefly, 1 – 5 × 106
CD34+ cells were centrifuged at 500 × g in 5 mL round bottom sterile tube and cells
resuspended in 1 mL of serum-free StemSpan® media (Stemcell Technologies, Vancouver,
BC). Lentiviral stock particles were added to 5 mL tube to the desired MOI and gently
mixed. Polybrene (Sigma, St. Louis, MO) was added to a final concentration of 4 μg/ml.
Cells were then centrifuged continuously at 1000 × g in a swinging bucket rotor for 120
minutes at ambient temperature. Finally, the supernatant was gently aspirated and the cells
resuspended in StemSpan® media supplemented with 50 ng/ml each of Flt-3 ligand, Stem
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cell factor 1 (SCF-1) and thrombopoietin (TPO) (Stemcell Technologies). UCB CD34+ cells
were initially expanded up to 10 days as described in the literature[24] and to increase the
number of transplanted UCB CD34+ cells to allow better in vivo imaging. Expansion was
carried out using StemSpan® media (Stemcell Technologies, Vancouver, BC) supplemented
with growth factors as described previously.
Transplantation of NSG mice
Institutional Animal Care and Use Committee approval was obtained prior to the animal
experiments. Six to eight week old female NSG mice, obtained from the Jackson
Laboratory, Bar Harbor, Maine, were maintained in the animal facilities at the University of
Kansas Medical Center. All animals were handled under sterile conditions as cages, water
bottles, water, and food were sterilized and animals were maintained in cage microisolators.
Mice were given a sublethal dose of 270 cGy using A J.L. Shepherd and Associates Mark I
Model 68A Cesium-137 source irradiator 24 hours prior to UCB CD34+cell infusion.
Animals were divided into two groups: HBO (n=37) and non-HBO (n=38) mice. (There
were 4 mice for each group at each time point except for month 4 time point where only 3
non-HBO mice survived for analysis. Also, one mouse was available for the HBO group and
three for the non-HBO group for the time point of 4 ½ months.) Twenty-four hours
following irradiation, the HBO mice received HBO therapy in a locally designed hyperbaric
chamber with 100% oxygen for 2 hours at 2.5 atmospheres absolute (ATA). Four hours after
the end of HBO therapy, HBO and control mice were ready for UCB CD34+ cell infusion.
UCB CD34+ cells (1 × 105 / 100 uL sterile PBS per mouse) were administered by tail vein
injection using a mouse restraint. The injected UCB CD34 cell dose was calculated based on
the total nucleated cell number and the percentage of CD34+ cells, determined by flow
cytometry, in the prepared UCB CD34+ sample the day of cell injection. Additional
irradiated mice (control) did not receive human UCB CD34+ cells and served as negative
controls. Using isoflurane inhalation, mice from HBO and non-HBO groups were
euthanized at the following time points: 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 4
weeks, 2 months, 3 months, 4 months, and 4.5 months. Four mice per group were euthanized
at each time point; except for the month 4 time point when only 3 non-HBO mice survived
and were available for analysis. Also, one mouse was available for the HBO group and three
for the non-HBO group for the time point of 4 ½ months. Peripheral blood, bone marrow,
and spleen were harvested and processed for engraftment as described later.
In vivo imaging
Unless otherwise indicated, mice (n=4 for each group for most time points) were imaged 1
day prior to their euthanization using IVIS Spectrum imaging unit. The following post-
transplant time points were assessed: 3 hours (only ventral as no dorsal activity was detected
in either group for this time point), 2 weeks, 4 weeks, 3 months and 4 months. For the 3 hour
time point, 5 mice from the non-HBO pool and 5 mice from HBO pool were grouped. These
mice were imaged also for one additional later time point. Imaging kinetics revealed peak
signal was achieved at 12 minutes and remained stable up to 25 minutes post injection.
Accordingly, we imaged the animals at 12 minute time-points. Briefly, animals were
injected with potassium salt of D-Luciferin (15 mg/ml at 10 μl/gm bodyweight) followed by
isoflurane induced anesthesia. Animals were imaged ventrally then dorsally, as ventral
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images correlate with engraftment in the sternum and rib cage while dorsal images correlate
with engraftment in the vertebral column and cranium[20]. Images were quantified using
living image software version 4.0. Region of interest (ROI) boxes were drawn around the
entire body (excluding tail) of the animals. Measurements were expressed as flux, i.e.
photons/second (p/s).
Staining of mouse peripheral blood and bone marrow for engraftment
Samples were stained using human CD45-FITC (Miltenyi Biotec, Bergisch Gladbach,
Germany), human CD3-PE-Cy5 (BD Biosciences, San Jose, CA), human CD19-APC
(Miltenyi Biotec) and human CD33-PE (Miltenyi Biotec) antibodies. Peripheral blood
samples were collected into heparinized microcapillary tubes, incubated in FcR Blocking
Reagent (Miltenyi Biotec), and stained with the appropriate antibody combination. Once
stained, the red blood cells (RBCs) were lysed using EasySep® RBC Lysis Buffer (Stemcell
Technologies, Vancouver, BC, Canada) per the manufacturer’s instructions, fixed in 2%
paraformaldehyde in PBS and washed in PBS with 1% FBS. Both femurs and tibiae were
collected for bone marrow harvest. Bone marrow samples were lysed for RBCs prior to
being blocked with FcR Blocking Reagent and stained with the appropriate antibody
combination. The cells were fixed with 2% paraformaldehyde in PBS and washed in PBS
with 1% FBS. Ten-thousand events were acquired for each peripheral blood and bone
marrow sample using the LSRII flow cytometer (BD Biosciences), and the data was
analyzed using FACSDiva software.
Statistical analysis
Scatter plots and descriptive statistics were generated. The general model building plan used
ordinary least squares (OLS) regression with backward elimination to derive the models.
The relationships of study measures over time for each treatment group were determined.
The exploratory flow cytometry models of this experiment allowed for separate curves by
group. Initial assessment of the full model utilized all possible terms for this model. Model
diagnostics included histograms of the residuals, quantile-quantile (q-q) plots, and plots of
residuals against both the predicted values and against time. Results of these diagnostic
evaluations led to the decision to utilize the natural log transformation of the response
measures to stabilize model’s variance, in keeping with the OLS assumptions of constant
variance. Factors were individually removed starting with the highest order interaction
terms, with a criteria of p>0.05 for the corresponding F test to remain in the model. In the
presence of higher ordered terms, all lower order effects were retained in the model.
Once the model was derived using the backwards elimination approach, contrast matrices
were used to test the global hypotheses that the resulting curves (if quadratic terms for time
remained in the model), lines (if linear terms were the highest order of time that remained in
the model), or means (if no time terms remained in the model) were equal. This was done
for each tissue-by-cell type combination. For the bioluminescence data, the backwards
elimination model building approach of was again used.
Due to the multiple measures analyzed in these studies, the approach to control experiment
wise type I error was as follows. CD45 measures in the bone marrow were considered the
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primary endpoint. The other measures (CD45 in other tissue; CD3, CD19, and
bioluminescence) were treated as secondary measures. Hence, no additional type I error
adjustments were included.
Results
Percentage of human UCB CD34+ cells pre- and post- transduction and expansion
Prior to transduction and expansion, human UCB units enriched for CD34+ cells contained
an average of 91.4% (+/- 4%) CD34+ cells. Post- transduction and expansion, UCB units
contained an average of 42% (+/- 37%) CD34+ cells. Expansion for less than 3 days resulted
in 89% (+/-7%) CD34+ UCB cells, while expansion of three or more days resulted in 14%
(+/-4%) CD34+ cells. For initial time points (24-72 hours) UCB CD34+ cells expanded up to
10 days were used for transplant. Because of the drop in CD34 percentage, for the remaining
time points, UCB CD34+ cells were expanded for less than 3 days.
HBO significantly improved peripheral blood, bone marrow, and spleen engraftment of
expanded and transduced human UCB CD34+ cells
In these experiments, we evaluated early peripheral blood, bone marrow, and spleen
retention of intravenously infused human UCB CD34+ cell by determining the percentage of
human CD45+ cells in the respective peripheral blood, bone marrow, and spleen tissue of
transplanted mice within 72 hours of UCB CD34+ cell infusion. We also evaluated
peripheral blood, bone marrow, and spleen engraftment by determining the percentage of
human CD45+ cells in the respective peripheral blood, bone marrow and spleen tissue of
transplanted mice starting at 1 week time point and up to 4 1/2 weeks following transplant.
UCB CD34+ cell tissue retention within 72 hours of UCB CD34+ cell infusion and
engraftment at later time points were assessed in the same tissue as a continuum. In our
model, HBO treated mice demonstrated significantly improved bone marrow (p=0.0067),
peripheral blood (p=0.0131), and spleen (p=0.0293) retention and subsequent engraftment
(Fig.1). The impact on engraftment in these tissues was more pronounced toward later
engraftment time points at 3 and 4 months. Collectively, these results suggest a potential
role for HBO in improving engraftment of UCB CD34+ cells.
HBO treated mice demonstrated significantly higher photon flux values
In these experiments, we used bioluminescent imaging to demonstrate repopulation of bone
marrow by transduced human CD34-selected umbilical cord blood (UCB) cells as described
previously[24]. We evaluated photon flux values obtained from in vivo images as a measure
of engraftment, as others have shown correlation between bioluminescence and
engraftment[25]. Higher dorsal and ventral photon flux values were observed in HBO
treated mice compared to non-HBO treated mice (Fig.2A). Again, the impact of HBO on
ventral photon flux values (p=0.0002) and dorsal photon flux values (p=0.0009) was more
pronounced at later time points (Fig.2B). Accordingly, the impact of HBO on engraftment
was universal without favoring certain bones for engraftment. On the other hand, HBO
treated mice demonstrated on average higher ventral photon flux values at the very early
time point of 3 hours (Fig.2C). In these images, bioluminescence activity was demonstrated
in the thoracic area of HBO mice. Baseline images taken within 10 minutes of UCB CD34+
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cell injection showed bioluminescence activity in mice thoraces consistent with trafficking
of the infused cells to the lungs. On the other hand, the 3 hour images of HBO mice were
more consistent with bioluminescence activity in the heart, given the central location of the
bioluminescence, and less likely related to entrapment of UCB CD34+ cells in the lungs.
These results suggest that HBO treatment might have altered early UCB CD34+ cell
distribution or viability and resulted in improvement in photon flux values overtime
mirroring engraftment data.
HBO significantly improved peripheral blood, spleen and bone marrow engraftment of
human CD19+ and CD33+ cell subsets while only increased peripheral blood engraftment
of CD3+ cells
We also determined if HBO impact on engraftment is related to improved engraftment of a
certain subset of hematopoietic cells. Accordingly, we evaluated human CD33+ cells for
myeloid engraftment, human CD19+ cells for B-cell engraftment, and human CD3+ cells for
T-cell engraftment starting 4 weeks following UC B CD34+ cell infusion. In terms of
CD33+ cell engraftment, it was significantly improved in peripheral blood (p=0.0091), bone
marrow (p=0.0066), and spleen (0.0399) of HBO treated mice (Fig.3A). Similar to overall
engraftment and B-cell engraftment patterns, the impact of HBO on CD33+ cell engraftment
was more pronounced at later time points (Fig.3A).
In the case of CD19+, statistically significant improvement in CD19+ cell engraftment in
peripheral blood (p=0.0016), bone marrow (p=0.0341), and spleen (p=0.0239) of HBO
treated mice was demonstrated (Fig.3B). Similar to overall engraftment, the impact of HBO
on engraftment was more pronounced at later time points for peripheral blood and bone
marrow (Fig.3B). CD3+ cell engraftment, on the other hand, was significantly increased in
peripheral blood (p=0.0032) of HBO treated mice (Fig.3C). Spleen and bone marrow CD3+
cell engraftment was comparable between HBO and non-HBO treated mice (p>0.05 for all
model terms related to treatment; thus removed from the model via backwards elimination).
Collectively, these data suggest that HBO improved overall engraftment mainly by
improving B-cell and myeloid cell engraftment.
Discussion
In these experiments we investigated the use of HBO as a modality to improve human UCB
CD34+ cell engraftment in sublethally irradiated NSG mice. We demonstrated that HBO
treatment prior to UCB CD34+ cell infusion significantly improved engraftment of
transduced and expanded UCB CD34+ cells, especially at later time points post-transplant.
Improved long-term engraftment is a desirable outcome in UCB transplantation where non-
engraftment remains a major complication of UCB transplantation. This procedure might be
of advantage when using gene transduced CD34+ UCB cells, as expansion itself may
decrease the homing characteristics of CD34+ cells.
In our experiments, we observed a significant impact of HBO on long-term engraftment of
the transduced and expanded UCB CD34+ cells. Following transduction, UCB CD34+ cells
were expanded using cytokine rich media to allow for their in vivo imaging and, as a result,
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we exposed these stem/progenitor cells to cytokines in the media. This exposure to
cytokines may have altered homing mechanisms in this model, as has been shown
previously[26]. Additionally, ex vivo cycling of hematopoietic stem cells results in changes
in polarized membrane domain. This change in membrane polarization may impair certain
adhesion molecules and, subsequently, the adhesion of hematopoietic stem cells to
osteoblasts. These changes seem to disrupt early events like hematopoietic stem cell
adhesion and homing and limit subsequent engraftment in NSG mice[27]. Due to these
potential effects of cytokine exposure, expanded UCB CD34+ cells might have lost
engraftment potential as has been described previously[28]. In our experiments, this loss
was potentially restored by using HBO, while the loss of engraftment was evident in the
case of non-HBO treated mice.
In our in vivo imaging experiments, we noticed that the difference in bioluminescence
between HBO and non-HBO treated mice to have widened overtime and at the same time
we noticed similar patterns for engraftment assessed by flow cytometry. These findings
suggest that bioluminescence at later time points correlates with long-term engraftment.
Consistent with this finding, others have found that bioluminescence in the first 3 weeks
post-transplant reflects engraftment of short-term repopulating progenitors, while
bioluminescence afterwards reflects engraftment of long-term repopulating progenitors[25].
Though HBO therapy was given prior to UCB CD34+ cell infusion and only for one
treatment, the effects of such therapy on engraftment became more pronounced at later time
points that correlate with long-term engraftment. Based on this observation, we hypothesize
that HBO treatment must have changed engraftment kinetics in favor of improved long-term
engraftment. Additionally, HBO supported peripheral blood engraftment of all lineages,
especially myeloid and B-cell lineages, in HBO mice. A skewed engraftment of CD19+ cell
population seems to occur upon repopulation of NOD/SCID mice by CD34+ UCB cells [29].
Outcomes of UCB transplantation reflect the interaction of the transplanted cells and the
recipient bone marrow microenvironment. Most current approaches to improve UCB
homing and engraftment involve manipulation of UCB unit, or graft, itself prior to
transplantation. The use of HBO to improve UCB engraftment is a new approach as it does
not involve graft manipulation, and instead may alter the host microenvironment conditions
in favor of engraftment.
HBO is considered a safe procedure when standard protocols with oxygen pressures not
exceeding 3 atmospheres and treatment sessions limited to a maximum of 120 minutes are
used [30]. Therefore, we are investigating HBO therapy in a pilot clinical trial to primarily
evaluate the safety and tolerability of this procedure in UCB transplantation. Secondarily,
we will also assess the impact of HBO on engraftment. Applying methods that improve
engraftment has the potential to greatly impact the application of this type of transplant to a
larger population in need.
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Figure-1. Impact of hyperbaric oxygen on umbilical cord blood CD34+ cell tissue retention/
engraftment measured by flow cytometry
Peripheral blood, bone marrow, and spleen homogenates were processed for human CD45
staining and flow cytometry to determine percentage of human CD45+ cell retention (up to
72 hours) or engraftment (data after 72 hours). The percentage of human CD45+ cells was
measured for each mouse and time point for each tissue. The data was log-transformed and
plotted on the scatter plot graph. Mean human CD45+ cells were connected for each group at
each time point (Blue: HBO, red: non-HBO, and green: control). In these experiments, HBO
mice demonstrated a statistically significant increase in the percentage of human CD45+
cells in peripheral blood, bone marrow, and spleen over non-HBO mice. The difference in
the percentage of human CD45+ cells between the two groups widened overtime.
Aljitawi et al. Page 11













Aljitawi et al. Page 12













Figure-2. Impact of hyperbaric oxygen (HBO) on umbilical cord blood CD34+ cell engraftment
determined by bioluminescence
Transplanted mice were imaged in vivo using IVIS spectrum imager. Prior to imaging, mice
were injected with D-Luciferin. Subsequently, mice were imaged ventrally then dorsally.
Images were quantified using living image software version 4.0 and) measurements were
expressed as flux i.e. photons/second (p/s). A: a representative in vivo image of the dorsal
aspect of HBO and non-HBO mice obtained at month 3 time point. A measureable
difference in bioluminescence signal between the 2 groups is demonstrated. Individual
scales are shown to correspond to bioluminescence. B: photon flux log transformed data
depicted in a scatter-plot. Mean photon flux values were connected for each group at each
time point (Blue: HBO and red: non-HBO). In these experiments, HBO mice demonstrated a
statistically significant increase in photon flux over non-HBO mice. The difference between
the two groups of mice was more significant at the later time points of 3 and 4 months. C: In
vivo imaging of the ventral aspect of HBO and non-HBO mice at baseline and 3 hours post-
transplant. At baseline, (10 minutes after UCB CD34+ cell injection) both groups of mice
demonstrated bioluminescence in the thoracic area. On the other hand, only HBO mice
demonstrated central thoracic bioluminescence 3-hours post-transplant. For the 3 hour time
point, 5 mice from the non-HBO pool and 5 mice from HBO pool were grouped.
Abbreviation: HBO stands for hyperbaric oxygen.
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Figure-3. Impact of hyperbaric oxygen on umbilical cord blood CD34+ cell subsets engraftment
Peripheral blood, bone marrow, and spleen were harvested from HBO and non-HBO mice.
Subset engraftment was assessed by flow cytometry staining for human CD33 (myeloid
subset-Fig.3A), human CD 19 (B-cell subset-Fig.3B), and human CD3 (T cell subset-Fig.
3C) antibodies. The percentage of human CD19, CD33, or CD3 positive cells was measured
for each mouse and time point for each tissue. The data was log-transformed and plotted on
the scatterplot graph. Mean human CD19, CD33, and CD3 positive cells were connected for
each group for each time point (Blue: HBO, red: non-HBO, and green: control). A: HBO
mice demonstrated a statistically significant increase in the percentage of human CD33+
cells in peripheral blood, bone marrow, and spleen over non-HBO mice. B:HBO mice
demonstrated a statistically significant increase in the percentage of human CD19+ cells in
peripheral blood, bone marrow, and spleen over non-HBO mice. The difference in the
percentage of human CD33+ and CD19+ cells between the two groups widened overtime. C:
HBO mice demonstrated a statistically significant increase in the percentage of human CD3+
cells across time only in peripheral blood compared to non-HBO mice.
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